atractylenolide I

02/01/2020 - "Establishment of a mouse model of cancer cachexia with spleen deficiency syndrome and the effects of atractylenolide I."
09/01/2008 - "A randomized pilot study of atractylenolide I on gastric cancer cachexia patients."
12/01/2022 - "Atractylenolide I ameliorates cancer cachexia through inhibiting biogenesis of IL-6 and tumour-derived extracellular vesicles."
02/01/2020 - "Oral administration of atractylenolide I (20 mg· kg-1per day, for 30 days) significantly ameliorated the reduction in body weight and atrophy of muscle, fat, spleen, and thymus in mice with spleen deficiency and cachexia. "
02/01/2020 - "In this study we established a new animal model of spleen deficiency and cancer cachexia in mice and evaluated the therapeutic effects of atractylenolide I, an active component of tonifying TCM BaiZhu, in the mouse model. "

01/01/2023 - "Atractylenolide I (Atr-I) was found to sensitize a variety of human cancer cells in previous studies. "
01/01/2021 - "Moreover, the Drp1 overexpression lentiviral vector was used to study the role of Drp1 on the signaling mechanisms of atractylenolide I. Atractylenolide I treatment significantly reduced the cell viability of human HCT116 and SW480 cells and induced apoptosis, and effectively inhibited colon tumors in the AOM/DSS mouse model. "
07/18/2014 - "Atractylenolide I (AT-I), one of the main naturally occurring compounds of Rhizoma Atractylodis Macrocephalae, has remarkable anti-cancer effects on various cancers. "
03/01/2002 - "However, atractylenolide I at 30 microg/ml for 12 h also induced apoptosis in HL-60 and P-388 cells, but atractylenolides II and III showed no significant inhibition effects on tumor cell growth. "
03/01/2020 - "Atractylenolide I (ATL-1) is a natural herbal compound used in traditional Chinese medicine that has exhibited anti-cancer properties. "

07/18/2014 - "Atractylenolide I-mediated Notch pathway inhibition attenuates gastric cancer stem cell traits."
09/01/2008 - "A randomized pilot study of atractylenolide I on gastric cancer cachexia patients."
09/01/2008 - "We determined the therapeutic efficacy of atractylenolide I (ATR), extracted from largehead atractylodes rhizome, in managing gastric cancer cachexia (GCC), and interpreted its probable pharmacological mechanism via investigating tumor necrosis factor alpha (TNF-alpha), interleukin-1 (IL-1), interleukin-6 (IL-6) and proteolysis-inducing factor (PIF). "

06/10/2009 - "To further investigate the anti-angiogenesis mechanism of atractylenolide I in cell and mice based on inflammation model, the vascular index and microvessel outgrowth were measured by using the Freunds complete adjuvant (FCA) induced mouse air pouch model as well as the mice aortic ring co-cultured with peritoneal macrophages model. "
06/10/2009 - "Atractylenolide I is an anti-inflammation agent. "
06/10/2009 - "Inhibitory effect of atractylenolide I on angiogenesis in chronic inflammation in vivo and in vitro."
11/01/2007 - "Oral administration of atractylenolide I and 14-acetoxy-12-senecioyloxytetradeca-2E,8E,10E-trien-4,6-diyn-1-ol produced significant anti-inflammatory effects in acute and chronic inflammation models in mice. "
01/01/2016 - "The protective effect of atractylenolide I on systemic inflammation in the mouse model of sepsis created by cecal ligation and puncture."

01/01/2016 - "Atractylenolide I modulates ovarian cancer cell-mediated immunosuppression by blocking MD-2/TLR4 complex-mediated MyD88/NF-κB signaling in vitro."
01/31/2017 - "Anti-Tumor Effects of Atractylenolide-I on Human Ovarian Cancer Cells."
01/23/2014 - "Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway."
01/31/2017 - "BACKGROUND The aim of this study was to investigate the effects of Atractylenolide-I (AT-I), a naturally occurring sesquiterpene lactone isolated from Atractylodes macrocephala Koidz, on human ovarian cancer cells. "